FARMACI ANTISECRETIVI, IPERGASTRINEMIA ED IPERPLASIA DELLE ECL

Translated title of the contribution: Anti-secretory drugs. Hypergastrinemia and ECL hyperplasia

A. Andriulli, A. Mangia, F. Lawson

Research output: Contribution to journalArticlepeer-review

Abstract

A review of the literature was carried out in order to identify those mechanisms responsible for hyperplasia of Enterocromaffin-like cells (ECL) undergoing treatment with anti-secretory drugs. All gastricc acid secretion-inhibiting drugs cause a physiological increase in gastrinemia due to their inhibitory function. ECL hyperplasia is the consequence of the duration of hypergastrinemia. To date no factors responsible for the possible transformation of hyperplasia into carcinoma have yet been identified.

Translated title of the contributionAnti-secretory drugs. Hypergastrinemia and ECL hyperplasia
Original languageItalian
Pages (from-to)135-140
Number of pages6
JournalMinerva Dietologica e Gastroenterologica
Volume37
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Anti-secretory drugs. Hypergastrinemia and ECL hyperplasia'. Together they form a unique fingerprint.

Cite this